Home > Drugs A – Z > Paliperidone (By injection)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Paliperidone injection is used to treat the symptoms of psychotic (mental) disorders, including schizophrenia. It may be used alone or in combination with other medicines to treat schizoaffective disorder. This medicine should not be used to treat behavioral problems in older adults who have dementia. This medicine is to be given only by or under the direct supervision of your doctor… Read more
Brand names include
Invega Sustenna, Invega Trinza
Other forms
By mouth
Drug classes About this
Antipsychotic

What works? Research summarized

Evidence reviews

Paliperidone palmitate for schizophrenia

Paliperidone palmitate is a long‐acting intramuscular formulation of paliperidone, an active metabolite of risperidone that was previously available only in an oral formulation. We evaluated the efficacy, adverse effects, and safety of paliperidone palmitate in the treatment of people with schizophrenia and schizophrenia‐like illnesses. In short‐term studies, paliperidone palmitate is a more effective antipsychotic than placebo. The adverse effects of paliperidone palmitate are similar to those of oral paliperidone, oral risperidone, and risperidone long‐acting injection. In two short‐term studies, flexibly‐dosed paliperidone palmitate is roughly equivalent in efficacy and tolerability to flexibly‐dosed risperidone long‐acting injection.

Three-month Injectable Paliperidone Palmitate for the Treatment of Adults with Schizophrenia: A Review of Clinical Effectiveness, Safety, and Guidelines [Internet]

This Rapid Response report aims to review the clinical effectiveness and safety of 3- month injectable paliperidone palmitate (PP3M) for schizophrenia compared with once-monthly injectable formulation (PP1M) and placebo in the treatment of adults with schizophrenia. Evidence-based guidelines regarding the use of 3-month injectable paliperidone palmitate for the adults with schizophrenia will also be examined.

Efficacy and safety of paliperidone palmitate in the treatment of schizophrenia: a meta-analysis

Bibliographic details: Huang Y, Liu GE, Gao C, Wang CZ, Ren XX, Liu YH.  Efficacy and safety of paliperidone palmitate in the treatment of schizophrenia: a meta-analysis. Chinese Pharmaceutical Journal 2014; 49(6): 517-522 Available from: http://c.wanfangdata.com.cn/periodical/zgyxzz/2014-6.aspx

See all (44)

Summaries for consumers

Paliperidone palmitate for schizophrenia

Paliperidone palmitate is a long‐acting intramuscular formulation of paliperidone, an active metabolite of risperidone that was previously available only in an oral formulation. We evaluated the efficacy, adverse effects, and safety of paliperidone palmitate in the treatment of people with schizophrenia and schizophrenia‐like illnesses. In short‐term studies, paliperidone palmitate is a more effective antipsychotic than placebo. The adverse effects of paliperidone palmitate are similar to those of oral paliperidone, oral risperidone, and risperidone long‐acting injection. In two short‐term studies, flexibly‐dosed paliperidone palmitate is roughly equivalent in efficacy and tolerability to flexibly‐dosed risperidone long‐acting injection.

Oral paliperidone for schizophrenia

Paliperidone, 9‐hydroxy‐risperidone, is an active metabolite of risperidone that is now commercially available in an oral formulation. We evaluated the efficacy, adverse effects, and safety of oral paliperidone in the treatment of people with schizophrenia and schizophrenia‐like illnesses. In short‐term studies, oral paliperidone is a more effective antipsychotic than placebo. The adverse effects of paliperidone are similar to those of risperidone. No data comparing the efficacy of paliperidone to risperidone over a meaningful period of time was available for this review; in a six‐day trial comparing paliperidone to risperidone we identified no difference in recurrence of psychotic symptoms or adverse effects. The manufacturer is also developing an intramuscular long‐acting formulation, but it is not yet commercially available; its use in the treatment of schizophrenia will be considered in a separate review.

Antipsychotic Medicines for Children and Teens: A Review of the Research for Parents and Caregivers

This summary discusses using antipsychotic medicines to treat psychiatric conditions in children. It explains what medical research says about the benefits and possible side effects of these medicines when taken by children. This summary does not discuss other medicines to treat psychiatric conditions or non-medicine treatment options. It can help you talk with your child’s doctor to decide if an antipsychotic medicine is right for your child.

See all (7)

PubMed Health Blog...

read all...